WPW
IBB icon

Waldron Private Wealth’s iShares Biotechnology ETF IBB Stock Holding History

Waldron Private Wealth’s Portfolio IBB Stock Details IBB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-2,286
Closed -$257K – 165
2015
Q4 		$257K Buy
+2,286
New +$248K 0.1% 124

Other funds holding IBB

Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
CB
Commerce Bank Kansas City, Missouri $20.7B AUM 23.76% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Waldron Private Wealth's IBB Position: Q1 2016 in Review

Waldron Private Wealth sold out of iShares Biotechnology ETF (IBB) in Q1 2016, closing a stake of 2,286 shares — an estimated $257K sold.

Waldron Private Wealth first reported a position in IBB in Q4 2015 and held it in 1 quarter. The position peaked at $257K in Q4 2015. 414 funds tracked by Wall St. Rank hold IBB as of Q1 2016.

  • Waldron Private Wealth reported no remaining iShares Biotechnology ETF position as of Q1 2016 after selling out during the quarter.
  • Waldron Private Wealth sold 2,286 iShares Biotechnology ETF shares in Q1 2016, an estimated $257K.
  • Waldron Private Wealth first reported a position in iShares Biotechnology ETF in Q4 2015 and held it in 1 quarter.
  • Waldron Private Wealth's iShares Biotechnology ETF position peaked at $257K in Q4 2015.
  • 414 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q1 2016.

Based on Waldron Private Wealth's 13F filing for Q1 2016, filed 9 May 2016.